BrainCo, a Chinese neurotechnology firm, is developing a wearable device that it says can suppress appetite by stimulating the brain. The company presents the approach as a non-drug alternative to GLP-1 weight-loss treatments, which have become widely used for obesity.
Both outlets describe the same core concept: an “electronic GLP-1” that targets eating behaviour through neural stimulation rather than medication. They also frame BrainCo’s work as a potential substitute or competitor to blockbuster GLP-1 therapies by aiming to reduce appetite directly.
While both reports converge on the device and its stated purpose, the emphasis differs slightly in wording. NDTV positions the effort as part of the broader narrative of “Elon Musk’s Chinese rival,” linking BrainCo to the attention around Neuralink. Bloomberg Technology focuses on the obesity angle and the “electronic” GLP-1 framing, treating the project primarily as a technology-led approach to weight loss.